Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Lenvatinib in Advanced Pancreatic Ductal Adenocarcinoma
NCT05273554Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2022
- Primary completion
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab and lenvatinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 1 year. Started Aug 2022; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05273554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05273554.